Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Myriad Genetics Inc's Business Segments
Myriad Genetics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
Cancer Care Continuum
Total Revenue
$ 191
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Cancer Care Continuum0%
- Prenatal Health42.8%
- Mental Health39.4%
- Non-US13.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cancer Care Continuum | $ 234 | - |
| Prenatal Health | $ 82 | 42.8% |
| Mental Health | $ 75 | 39.4% |
1 more segments available
Sign in to unlock the full Myriad Genetics Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Cancer Care Continuum0%
- Prenatal Health42.8%
- Mental Health39.4%
- Non-US13.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Cancer Care Continuum | $ 234 | - |
| Prenatal Health | $ 82 | 42.8% |
| Mental Health | $ 75 | 39.4% |
1 more segments available
Sign in to unlock the full Myriad Genetics Inc dataset.
Description of Myriad Genetics Inc
Myriad Genetics Inc.
is a leading biotechnology company in the United States that specifically focuses on the development and commercialization of molecular diagnostic tests.
The company is based in Salt Lake City, Utah and was founded in 1991.
Myriad Genetics is widely recognized for its innovative diagnostic tests, which help assess the risk of developing certain diseases, including inherited cancers, cardiovascular diseases, neurological disorders, and other genetic conditions.
The company has developed several proprietary technologies that enable its diagnostic tests to provide highly accurate and reliable results.
Myriad Genetics' most well-known product is its BRACAnalysis test, which is used to identify mutations in the BRCA1 and BRCA2 genes.
These mutations have been linked to breast and ovarian cancer, and the BRACAnalysis test is a key tool in helping healthcare professionals assess patients' risk of developing these diseases.
Myriad Genetics has also developed a range of other diagnostic tests, including its myRisk Hereditary Cancer test, which assesses the risk of developing several hereditary cancers using a multi-gene panel.
The company has also expanded into the field of companion diagnostics, working with pharmaceutical companies to develop tests that can identify patients who are likely to respond to specific treatments.
In addition to its diagnostic products, Myriad Genetics also operates a research and development division, which is dedicated to discovering new diagnostic and therapeutic technologies.
Myriad Genetics has received numerous awards and honors for its innovative work, including being named one of the world's most innovative companies by Forbes magazine.
As of 2021, Myriad Genetics has over 2,600 employees worldwide and its products are used in over 100 countries.
The company remains committed to advancing genetic testing and personalized medicine, with a focus on providing patients and healthcare professionals with the most accurate and reliable diagnostic information possible.
is a leading biotechnology company in the United States that specifically focuses on the development and commercialization of molecular diagnostic tests.
The company is based in Salt Lake City, Utah and was founded in 1991.
Myriad Genetics is widely recognized for its innovative diagnostic tests, which help assess the risk of developing certain diseases, including inherited cancers, cardiovascular diseases, neurological disorders, and other genetic conditions.
The company has developed several proprietary technologies that enable its diagnostic tests to provide highly accurate and reliable results.
Myriad Genetics' most well-known product is its BRACAnalysis test, which is used to identify mutations in the BRCA1 and BRCA2 genes.
These mutations have been linked to breast and ovarian cancer, and the BRACAnalysis test is a key tool in helping healthcare professionals assess patients' risk of developing these diseases.
Myriad Genetics has also developed a range of other diagnostic tests, including its myRisk Hereditary Cancer test, which assesses the risk of developing several hereditary cancers using a multi-gene panel.
The company has also expanded into the field of companion diagnostics, working with pharmaceutical companies to develop tests that can identify patients who are likely to respond to specific treatments.
In addition to its diagnostic products, Myriad Genetics also operates a research and development division, which is dedicated to discovering new diagnostic and therapeutic technologies.
Myriad Genetics has received numerous awards and honors for its innovative work, including being named one of the world's most innovative companies by Forbes magazine.
As of 2021, Myriad Genetics has over 2,600 employees worldwide and its products are used in over 100 countries.
The company remains committed to advancing genetic testing and personalized medicine, with a focus on providing patients and healthcare professionals with the most accurate and reliable diagnostic information possible.
Myriad Genetics Inc. is a prominent biotechnology and genomics company based in the United States, renowned for its commitment to advancing the field of genetic testing. Myriad leverages its expertise to offer a diverse portfolio of products and services that empower healthcare providers and enhance patient care through precision medicine. The companys operations are primarily categorized into the following segments, products, and services:
Segments
1. Genetic Testing Segment:
This is the cornerstone of Myriad Genetics business model. The genetic testing segment includes a wide array of molecular diagnostic tests designed to identify hereditary cancer risks, neuropsychiatric conditions, and rare genetic disorders. Utilizing proprietary technology, Myriad aims to deliver comprehensive genetic insights that facilitate early diagnosis, risk assessment, and informed decision-making for both patients and healthcare providers.
2. Pharmaceutical Segment:
Myriad’s Pharmaceutical segment concentrates on the development of companion diagnostic tests that accompany specific therapeutic drugs. These diagnostic tests assess the likelihood of patients responding positively to certain medications based on their unique genomic profiles. This personalized approach enhances treatment efficacy and minimizes adverse effects by ensuring that therapies are tailored to the individuals genetic characteristics.
Products
1. Hereditary Cancer Products:
- BRACAnalysis: This pioneering test assesses an individual’s risk of hereditary breast and ovarian cancers by identifying mutations in the BRCA1 and BRCA2 genes. It is notable for being the first of its kind to offer definitive risk assessment to women with familial predispositions to these cancers.
- COLARIS: A test that evaluates genes associated with colorectal cancer. It helps identify individuals at increased risk for Lynch syndrome, thereby enabling proactive surveillance and risk reduction strategies.
- Prolaris: This product measures the expression of genes related to prostate cancer aggressiveness, providing insights that aid in clinical decisions regarding treatment strategies for those diagnosed with prostate cancer.
2. Neuropsychiatric Products:
- GeneSight: This pharmacogenomic test assists healthcare providers in selecting optimal antidepressant medications tailored to an individual’s genetic profile. GeneSight analyzes genetic variants that influence drug metabolism and response, aiding clinicians in mitigating trial-and-error prescribing.
3. Rare Disease Products:
- Vectra: Vectra is a sophisticated multi-biomarker blood test that evaluates disease activity in rheumatoid arthritis patients. This innovative tool aids in monitoring treatment responses and managing the disease over time, helping to optimize therapeutic strategies for patients.
Services
1. Diagnostic Testing Services:
Myriad Genetics provides comprehensive diagnostic testing services that support physicians in diagnosing a variety of genetic disorders. These services are intended to facilitate early detection and treatment of conditions that may otherwise go undiagnosed, improving patient outcomes and quality of life.
2. Companion Diagnostic Services:
The company offers companion diagnostic services that are critical for identifying patients who are most likely to benefit from specific therapeutic interventions. By aligning drug therapies with the patient’s genetic makeup, Myriad strengthens the foundation of personalized medicine, enabling healthcare professionals to make more precise and effective treatment choices.
Conclusion
In summary, Myriad Genetics Inc. stands at the forefront of the genetic testing landscape, delivering a comprehensive suite of products and services that address critical needs in hereditary cancer assessment, neuropsychiatric treatment optimization, and rare disease diagnosis. Through its innovative genetic testing solutions and companion diagnostic services, Myriad facilitates informed clinical decision-making, paving the way for personalized and effective medical care. These advancements not only benefit healthcare providers but also significantly enhance the overall outcomes for patients.
Segments
1. Genetic Testing Segment:
This is the cornerstone of Myriad Genetics business model. The genetic testing segment includes a wide array of molecular diagnostic tests designed to identify hereditary cancer risks, neuropsychiatric conditions, and rare genetic disorders. Utilizing proprietary technology, Myriad aims to deliver comprehensive genetic insights that facilitate early diagnosis, risk assessment, and informed decision-making for both patients and healthcare providers.
2. Pharmaceutical Segment:
Myriad’s Pharmaceutical segment concentrates on the development of companion diagnostic tests that accompany specific therapeutic drugs. These diagnostic tests assess the likelihood of patients responding positively to certain medications based on their unique genomic profiles. This personalized approach enhances treatment efficacy and minimizes adverse effects by ensuring that therapies are tailored to the individuals genetic characteristics.
Products
1. Hereditary Cancer Products:
- BRACAnalysis: This pioneering test assesses an individual’s risk of hereditary breast and ovarian cancers by identifying mutations in the BRCA1 and BRCA2 genes. It is notable for being the first of its kind to offer definitive risk assessment to women with familial predispositions to these cancers.
- COLARIS: A test that evaluates genes associated with colorectal cancer. It helps identify individuals at increased risk for Lynch syndrome, thereby enabling proactive surveillance and risk reduction strategies.
- Prolaris: This product measures the expression of genes related to prostate cancer aggressiveness, providing insights that aid in clinical decisions regarding treatment strategies for those diagnosed with prostate cancer.
2. Neuropsychiatric Products:
- GeneSight: This pharmacogenomic test assists healthcare providers in selecting optimal antidepressant medications tailored to an individual’s genetic profile. GeneSight analyzes genetic variants that influence drug metabolism and response, aiding clinicians in mitigating trial-and-error prescribing.
3. Rare Disease Products:
- Vectra: Vectra is a sophisticated multi-biomarker blood test that evaluates disease activity in rheumatoid arthritis patients. This innovative tool aids in monitoring treatment responses and managing the disease over time, helping to optimize therapeutic strategies for patients.
Services
1. Diagnostic Testing Services:
Myriad Genetics provides comprehensive diagnostic testing services that support physicians in diagnosing a variety of genetic disorders. These services are intended to facilitate early detection and treatment of conditions that may otherwise go undiagnosed, improving patient outcomes and quality of life.
2. Companion Diagnostic Services:
The company offers companion diagnostic services that are critical for identifying patients who are most likely to benefit from specific therapeutic interventions. By aligning drug therapies with the patient’s genetic makeup, Myriad strengthens the foundation of personalized medicine, enabling healthcare professionals to make more precise and effective treatment choices.
Conclusion
In summary, Myriad Genetics Inc. stands at the forefront of the genetic testing landscape, delivering a comprehensive suite of products and services that address critical needs in hereditary cancer assessment, neuropsychiatric treatment optimization, and rare disease diagnosis. Through its innovative genetic testing solutions and companion diagnostic services, Myriad facilitates informed clinical decision-making, paving the way for personalized and effective medical care. These advancements not only benefit healthcare providers but also significantly enhance the overall outcomes for patients.